



Quarterly report of

MILESTONE MEDICAL, INC.

2nd quarter (from April 1, 2014 to June 30, 2014)

Report include:

1. General information about Milestone Medical, Inc
2. Condensed quarterly financial statements prepared according to the accounting rules applicable to the issuer together with information on accounting rules (policy) applied to the preparation of report.
3. Information on the rules applied to the preparation of the report, including information on changes to the applied accounting rules (policies).
4. Brief description of the most important achievements or failures of the issuer during the period of the report as well as a description of the most important factors and events, in particular atypical ones, which impact the achieved results
5. A description of the status of implementation of activities and investments of the issuer and the timetable of their implementation
6. If the issuer took initiatives to develop its activities aimed to implement innovative solutions at the enterprise during the period of the report – information on such activities
7. Description of the organization of the group indicating consolidated entities

New Jersey, August 14, 2014

1. General information

THE ISSUER	MILESTONE MEDICAL, INC. (earlier: Milestone Scientific Research and Development, Inc.)
Registered office/Office:	220 South Orange Avenue, Livingston, NJ 07039, USA
Telephone number:	011-973-535-2717
Facsimile number:	011-973-535-2829
E-mail:	jdagostino@milestonescientific.com
Main website address:	www.medicalmilestone.com

Source: The Issuer

1.1. Shareholding structure

In below table shares issuable pursuant to options or warrants are not deemed to be outstanding for computing the ownership percentage of shareholders holding at least 5% of votes at the general meeting, because currently outstanding shares can vote at the general meeting. For this reason applicable percentages are based on 22,000,000 shares outstanding on the date of this quarterly report preparation. All percentages are rounded.

Table 1 Shareholder structure with specification of shareholders holding at least 5% of votes at the general meeting

Name of Shareholder	Number of owned shares/votes	Shareholding/votes at General Meeting of Shareholders [%]
MILESTONE SCIENTIFIC, INC.	10,000,000	45.45%
FENG YULIN*	2,000,000	9.09%
DONG BINGMEI*	2,000,000	9.09%
ZHU YUN*	1,600,000	7.27%
WANG TAO*	1,600,000	7.27%
OTHERS (<5%)	4,800,000	21.83%
TOTAL	22,000,000	100%

Source: The Issuer

*These shareholders are controlling shareholders of Beijing 3H, the Joint-Venture partner with Milestone Scientific, Inc., as discussed in Note 1 of the unaudited financial statements.

1.2. Board of Directors

Table 2 Board of Directors

NAME OF DIRECTOR	CURRENT AGE	DIRECTOR SINCE	END OF TERM
Leonard A. Osser	67	March 2011	Next Annual Meeting of Shareholders
Feng Yulin	48	March 2011	Next Annual Meeting of Shareholders
Zhu Yun	48	September 2013	Next Annual Meeting of Shareholders
Martin S. Siegel	69	September 2013	Next Annual Meeting of Shareholders

Source: The Issuer

1.3. Information on the number of persons employed by the issuer converted into FTEs

On June 30, 2014 the Issuer employed two full time employees and three (3) persons converted into full-time equivalents ("FTEs").

2. Condensed quarterly financial statements prepared according to the accounting rules applicable to the issuer together with information on accounting rules (policy) applied to the preparation of report

Milestone Medical Inc.
(A Development Stage Company)
Formerly known as Milestone Scientific Research & Development Inc.

FINANCIAL STATEMENTS

Three and six months ended June 30, 2014 and 2013

Year ended December 31, 2013

And from March 8, 2011 (Inception) to June 30, 2014

CONTENTS

	<u>Page</u>
Financial Statements:	
Balance Sheets	2
Statements of Operations	3
Statements of Changes in Stockholders' Equity	4
Statements of Cash Flows	5
Notes to Financial Statements	6-11

MILESTONE MEDICAL

MILESTONE MEDICAL INC.
(A DEVELOPMENT STAGE COMPANY)
(Formerly known as MILESTONE SCIENTIFIC RESEARCH & DEVELOPMENT INC.)
BALANCE SHEETS

<u>ASSETS</u>	<u>June 30, 2014</u> (Unaudited)	<u>December 31, 2013</u> (Audited)
Current Assets:		
Cash	\$ 1,352,419	\$ 1,881,910
Prepaid expenses and other current assets	2,442	4,825
Advances to contractors	372,074	372,074
Inventory	12,319	-
Total current assets	<u>1,739,254</u>	<u>2,258,809</u>
Equipment, net of accumulated depreciation of \$23,571 as of June 30, 2014 and \$15,871 as of December 31, 2013	53,430	61,130
Intangible Asset	1,500,000	1,500,000
Total assets	<u>\$ 3,292,684</u>	<u>\$ 3,819,939</u>
<u>LIABILITIES AND STOCKHOLDERS' EQUITY</u>		
Current Liabilities:		
Accounts payable and accrued expense	\$ 163,540	\$ 125,962
Total current liabilities	<u>163,540</u>	<u>125,962</u>
Commitments and Contingencies		
Stockholders' Equity		
Preferred stock, par value \$.0001; authorized 5,000,000 shares; 0 shares issued		
Common stock, par value \$.0001; authorized 50,000,000 shares; 22,000,000 shares issued and outstanding at June 30, 2014 and December 31, 2013	2,200	2,200
Additional paid-in capital	6,318,185	6,126,834
Accumulated deficit during the development stage	<u>(3,191,241)</u>	<u>(2,435,057)</u>
Total stockholders' equity	<u>3,129,144</u>	<u>3,693,977</u>
Total liabilities and stockholders' equity	<u>\$ 3,292,684</u>	<u>\$ 3,819,939</u>

See Notes to Financial Statements

MILESTONE MEDICAL

MILESTONE MEDICAL INC.
(A DEVELOPMENT STAGE COMPANY)
(Formerly known as MILESTONE SCIENTIFIC RESEARCH & DEVELOPMENT INC.)
STATEMENTS OF OPERATIONS

	<u>Three Months Ended</u> <u>June 30, 2014</u> <small>(unaudited)</small>	<u>Three Months Ended</u> <u>June 30, 2013</u> <small>(unaudited)</small>	<u>Six Months Ended</u> <u>June 30, 2014</u> <small>(unaudited)</small>	<u>Six Months Ended</u> <u>June 30, 2013</u> <small>(unaudited)</small>	<u>Year Ended</u> <u>December 31, 2013</u> <small>(audited)</small>	<u>March 8, 2011</u> <u>(Inception) to</u> <u>June 30, 2014</u> <small>(unaudited)</small>
Revenue	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
Research and development expenses	83,685	225,380	115,261	225,380	315,124	1,589,445
Expenses:						
Shared Services	121,649	179,571	180,351	179,571	409,828	796,179
Depreciation	3,850	3,294	7,700	3,294	15,400	23,571
General and administrative expenses	259,847	18,193	452,872	19,676	279,254	782,046
Total expenses	<u>469,031</u>	<u>426,438</u>	<u>756,185</u>	<u>427,921</u>	<u>1,019,606</u>	<u>3,191,241</u>
Net loss	<u>\$ (469,031)</u>	<u>\$ (426,438)</u>	<u>\$ (756,185)</u>	<u>\$ (427,921)</u>	<u>\$ (1,019,606)</u>	<u>\$ (3,191,241)</u>
Net loss applicable to common stockholders	<u>\$ (469,031)</u>	<u>\$ (426,438)</u>	<u>\$ (756,185)</u>	<u>\$ (427,921)</u>	<u>\$ (1,019,606)</u>	<u>\$ (3,191,241)</u>

See Notes to Financial Statements

MILESTONE MEDICAL INC.
(A DEVELOPMENT STAGE COMPANY)
(Formerly known as MILESTONE SCIENTIFIC RESEARCH & DEVELOPMENT INC.)
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(Unaudited)

	Common Stock		Additional Paid-in Capital	Accumulated Deficit During the Development Stage	Total
	Shares (in thousands)	Amount			
Balance, March 8, 2011 (Inception)	\$ -	\$ -	\$ -	\$ -	\$ -
Beijing 3H - Capital contributions received	-	-	670,000	-	670,000
Common stock issued to Milestone Scientific Inc on April 21, 2011 for Intangible Asset for technology rights	10,000	1,000	1,499,000	-	1,500,000
Net Loss	-	-	-	(243,298)	(243,298)
Balance, December 31, 2011	10,000	1,000	2,169,000	(243,298)	1,926,702
Beijing 3H - Capital contributions received	-	-	830,000	-	830,000
Common Stock issued to Beijing 3H on August 14, 2012	10,000	1,000	(1,000)	-	-
Contributed Capital-Milestone Scientific Inc Shared Service Expense	-	-	206,000	-	206,000
Net Loss	-	-	-	(1,172,153)	(1,172,153)
Balance, December 31, 2012	20,000	2,000	3,204,000	(1,415,451)	1,790,549
Contributed Capital-Milestone Scientific Inc Shared Service Expense	-	-	409,828	-	409,828
Capital contribution received (cash) shareholders in July and August 2013	-	-	150,000	-	150,000
Net proceeds on Private Placement Offering in November and December 2013	2,000	200	2,363,006	-	2,363,206
Net Loss	-	-	-	(1,019,606)	(1,019,606)
Balance, December 31, 2013	22,000	\$ 2,200	\$ 6,126,834	\$ (2,435,057)	\$ 3,693,977
Contributed Capital-Milestone Scientific Inc Shared Service Expense	-	-	191,351	-	191,351
Net Loss	-	-	-	(756,185)	(756,185)
Balance, June 30, 2014	22,000	\$ 2,200	\$ 6,318,185	\$ (3,191,241)	\$ 3,129,144

See Notes to Financial Statements

MILESTONE
MEDICAL

MILESTONE MEDICAL INC.
(A DEVELOPMENT STAGE COMPANY)
(Formerly known as MILESTONE SCIENTIFIC RESEARCH & DEVELOPMENT INC.)
STATEMENTS OF CASH FLOWS

	<u>Six months ended</u> <u>June 30, 2014</u> (Unaudited)	<u>Year Ended</u> <u>December 31, 2013</u> (Audited)	March 8, 2011 (Inception) to <u>June 30, 2014</u> (Unaudited)
Cash flows from operating activities:			
Net loss	\$ (756,185)	\$ (1,019,606)	\$ (3,191,241)
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation expense	7,700	15,400	23,571
Contributed Capital - Milestone Scientific Inc Shared Services Expense	191,351	409,828	807,179
Changes in operating assets and liabilities:			
Increase in inventories	(12,319)	-	(12,319)
Increase in advances to contractors	-	(353,946)	(372,074)
Decrease (Increase) to prepaid expenses and other current assets	2,383	(4,825)	(2,442)
Increase in accounts payable and accrued expenses	37,579	123,804	163,540
Net cash used in operating activities	<u>(529,491)</u>	<u>(829,345)</u>	<u>(2,583,786)</u>
Cash flows from investing activities:			
Purchase of equipment	-	-	(77,000)
Net cash used in investing activities	<u>-</u>	<u>-</u>	<u>(77,000)</u>
Cash flows from financing activities:			
Proceeds from sale of stock (initial capital)	-	-	1,500,000
Capital contribution received (cash) - shareholder	-	150,000	150,000
Net Proceeds of Private Placement Offering	-	2,363,206	2,363,206
Net cash provided by financing activities	<u>-</u>	<u>2,513,206</u>	<u>4,013,206</u>
NET (DECREASE) INCREASE IN CASH	(529,491)	1,683,861	1,352,419
Cash at beginning of period	1,881,910	198,049	-
Cash at end of period	<u>\$ 1,352,419</u>	<u>\$ 1,881,910</u>	<u>\$ 1,352,419</u>
Supplemental disclosure of non cash activities:			
Contributed Capital - Milestone Scientific Inc Shared Services Expense	<u>\$ 191,351</u>	<u>\$ 409,828</u>	<u>\$ 807,179</u>
Issuance of 10,000 shares of common stock in exchange for intangible assets	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 1,500,000</u>

See Notes to Financial Statements

**NOTES TO CONDENSED FINANCIAL STATEMENTS
(UNAUDITED)
June 30, 2014**

NOTE 1 - ORGANIZATION:

In March 2011, Milestone Scientific Inc entered into an agreement with Beijing 3H Scientific Technology Co, Ltd ("Beijing 3H") a medical equipment distribution company organized in the People's Republic of China ("PRC"), to establish a medical joint venture entity now named Milestone Medical Inc. (the "Company") to develop intra-articular and epidural drug delivery instruments. The controlling shareholders of Beijing 3H and other shareholders contributed \$1.5 million in cash for a 50% ownership interest in this medical joint venture and Milestone Scientific Inc. contributed a royalty - free right to use its patented CompuFlo Technology, which was valued initially at \$1.5 million for the remaining 50% ownership interest.

The Company is incorporated in the State of Delaware and is in its development stage. This stage is characterized by significant expenditures for the development, commercialization and for regulatory approval for two medical instruments. As of June 30, 2014, the Company has not yet obtained regulatory approval. As a development stage company, the Company is limited to expending funds provided by its stockholders. In 2014, the Company entered into a commercial mode with the commitment to purchase 500 instruments (250 epidural and 250 intra-articular instruments). These instruments have progressed beyond the development stage and are now awaiting final regulatory marketing clearance in the USA (FDA) and the European Union (CE). In the interim, introductory meetings are being held with medical device distributors. Once the Company's planned principal operations commence, its focus will be on the marketing its two instruments throughout the world.

In June 2013, the Company changed its name to Milestone Medical Inc. The Company changed its Certificate of Incorporation to authorize 50,000,000 common shares, par value \$0.0001 per share and authorized 5,000,000 Preferred Shares, (preferred stock) at \$0.0001 per share in September 2013. Additionally, the common stock outstanding was split 10,000 to 1 into an aggregate of 20,000,000 shares. All periods presented have been recast to reflect these changes.

The Company has incurred operating losses since its inception. The Company has used cash in operations since inception of approximately \$3.2 million. In November 2013, the Company raised \$2,363,206 in net proceeds (gross funding was \$3 million) through a Private Placement Offering. The offering resulted in the issuance of 2 million shares of common stock at \$1.50 (4.65 PLN) per share in a private placement in Poland. As a result of the offering and the receipt of the net proceeds, the Company believes it will have sufficient cash flow to continue on its plan for the commercialization of the medical instruments over the next twelve months.

The unaudited financial statements of Milestone Medical Inc., have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information.

NOTE 1 - ORGANIZATION: (Continued)

Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements.

These unaudited financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2013 included in Milestone Medical Inc's Annual Report.

In the opinion of management, the accompanying unaudited financial statements contain all adjustments (consisting of normal recurring entries) necessary to fairly present Milestone Medical Inc's financial position as of June 30, 2014 and the results of its operations for the three and six months then ended.

The results reported for the three and six months ended June 30, 2014 are not necessarily indicative of the results of operations which may be expected for a full year.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Basis of Accounting

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

Use of Estimates

In preparing financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the reporting period. Actual results could differ from those estimates.

Advances to Contractors

The advances to contractors represent funding to a subcontractor, in the fourth quarter for year ended December 31, 2013, for advances on parts required to produce both epidural and intra articular instruments. The advance is expected to be utilized in 2014.

Equipment

Equipment (molds for pre-production and commercialized instruments) are recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which is five years. The costs of maintenance and repairs are charged to operations as incurred.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (Continued)

Intangible Asset

In connection with the formation and capitalization of the Company, the business was valued at inception using the discounted cash flow method, which resulted in a valuation of approximately \$3 million. The Company allocated the business valuation between the cash that Beijing 3H agreed to contribute (\$1.5 million) and the remaining \$1.5 million was allocated to Milestone Scientific Inc.'s contribution of a royalty-free right to use its patented *CompuFlo* technology (intangible asset). The Company will begin amortizing the intangible asset contributed when either of the two medical instruments has been commercialized. The asset's estimated useful life will be based on the average remaining life of the underlying patents. In the development stage the Company assesses the intangible asset for impairment at each reporting period or sooner if there are indicators that trigger an earlier assessment. The Company's impairment assessment is based on several factors including the progress made in developing the two medical instruments, the results from the research performed by the vendor, the Company's ability to use its technical capabilities to forecast the outcome of the research being performed and more recently feedback received from professionals as the Company applies for regulatory approval.

All these factors indicate that the technology continues to be feasible to be used in the two instruments being developed. Accordingly, no impairment has been recorded in these financial statements for the periods being reported.

Research and Development

Research and development costs are expensed as incurred. A portion of the Company's research and development efforts are sub-contracted to vendors and progress is monitored periodically.

Income Taxes

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets, including tax loss and credit carryforwards, and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized.

Accounting for Uncertain Tax Positions

The Company follows the Income Taxes Topic of the FASB Accounting Standards Codification, which provides clarification on accounting for uncertainty in income taxes recognized in the Company's financial statements. The guidance prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provides guidance on derecognition, classification, interest and penalties, disclosure and transition.

At June 30, 2014 and December 31 2013, no significant income tax uncertainties have been included in the Company's financial statements.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: (Continued)

The Company's policy is to recognize interest and penalties on unrecognized tax benefits in income tax expense in the statement of operations. No interest and penalties have been incurred for the six months ended June 30, 2014, year ended December 31, 2013 and for the period March 8, 2011 (inception) to June 30, 2014. Tax returns since inception are subject to audit by federal and state jurisdictions.

Services Provided by Stockholder

The Company is provided management, financial, engineering and accounting services by the staff of Milestone Scientific, Inc, its joint venture partner. The joint venture partners formalized this agreement in writing during the third quarter of 2013. The value related to these services are charged to the Company on a periodic basis. These charges are included in the financial statements as shared service expense. Additional Paid in Capital has been credited for the rendered services.

Subsequent Events

Management has evaluated subsequent events through August 14, 2014, the date the financial statements are available to be issued, for inclusion or disclosure in the financial statements.

NOTE 3 - JOINT VENTURE AGREEMENT:

In connection with the Joint Venture Agreement between Milestone Scientific Inc and Beijing 3H, the controlling shareholders of Beijing 3H and other shareholders contributed \$1.5 million, to the Company. \$670,000 in 2011 and \$830,000 in 2012 for a fifty (50) percent ownership. At inception, the Company reviewed this transaction to assess the technological feasibility of the products being developed. Based on the following factors, the Company believed the technology was feasible from inception.

- Milestone Scientific Inc. patented its CompuFlo technology in several instruments.
- The patents were generic for use in the medical and dental markets when granted.
- The capabilities to use this technology existed from CompuFlo technology and as technology evolved the Company has improved the technology over a number of years.
- The Director of Clinical Affairs of the Company was involved significantly in developing these patents initially and his conclusions are that technology is feasible for use in medical devices.

Milestone Scientific Inc. was authorized by the joint venture agreement to manage and oversee the development of the two medical instruments for the Company. In connection with this, Milestone Scientific Inc. entered into an agreement with a vendor to develop the two instruments. Milestone personnel monitored the development of the instruments with the third party vendors on a periodic basis thus ensuring that the instruments are being developed on a timely basis. Milestone Scientific Inc. will have distribution responsibility in the U.S. and Canada, while Beijing 3H will distribute products exclusively in the PRC, Macao, Hong Kong and other regions of Asia. The Company will have distribution responsibilities for the rest of the world.

NOTE 4 - STOCKHOLDERS' EQUITY:

In July 2013, the Company requested additional total capital contribution of \$150,000 from its two joint venture partners. In August 2013, such funds were deposited in the Company's cash account.

In June 2013, the Company entered an agreement with an agent in Poland to provide assistance in raising capital in a Private Placement Memorandum (PPM). Such amount raised in the PPM, were subject to the Company's approval and subsequent listing on the Warsaw Stock Exchange in Poland. The agreement called for a service fee payable to the agent upon consummation and the amount was deducted as described below. In addition, the Company entered a three year advisory agreement with a firm in Poland for their services provided capital is raised and shares of common stock are listed on the stock exchange.

In October and November 2013, the Company signed subscription agreements for the sale of 2 million shares of the Company's common stock at \$1.50 (4.65 PLN) per share (\$3 million capital raised - net proceeds of \$2,363,006) in a private placement in Poland. The consummation of the private placement was subject to the satisfaction of all closing conditions including, but not limited to, the admission of the Company's common stock for trading in the Alternative Trading System on the NewConnect Market of the Warsaw Stock Exchange in Poland. As of December 2013, the payment by the new investors was fully received and the 2 million shares were registered on the NewConnect Market of the Warsaw Stock Exchange.

NOTE 5 - RELATED PARTY TRANSACTIONS:

The Company is owned by Milestone Scientific Inc., Beijing 3H and a group of investors (owning approximately nine percent of the outstanding shares). The Company reimbursed approximately \$105,000 of previous research and development expenditures to Milestone Scientific Inc. in 2011. The Company periodically reimburses Milestone Scientific Inc. for the travel and other costs related to the business of the Company. The total expenses reimbursed for travel were \$1,261, \$1,261, \$28,126 and \$46,343 for the three and six months ended June 30, 2014, year ended December 31, 2013 and from March 8, 2011 (Inception) to June 30, 2014, respectively.

The Company is provided management, financial, engineering and accounting services by the staff of Milestone Scientific, Inc.

In December 2012, the Company purchased equipment for \$77,000 from a supplier who is also an investor in the Company and Milestone Scientific, Inc.

For the three and six months ended June 30, 2014, year ended December 31, 2013 and for the period March 8, 2011 (Inception) to June 30, 2014, the Company reimbursed Milestone Scientific Inc \$107,877, \$132,431, \$322,530 and \$576,885, respectively for expenses paid by Milestone Scientific Inc. for the benefit of the Company and the amount owed to Milestone Scientific, Inc at June 30, 2014 is \$55,424.

NOTE 5 - RELATED PARTY TRANSACTIONS: (Continued)

Milestone Scientific Inc. charged expenses to the Company based on estimated time expended on the development, supervision and management of the project. For the three and six months ended June 30, 2014, year ended December 31, 2013 and from March 8, 2011 (Inception) to June 30, 2014, Milestone Scientific Inc. expended approximately \$92,000 and \$131,000, \$226,000 and \$357,000, respectively, on regulatory legal fees (FDA Regulations). The Company charged \$29,000, \$49,000, \$184,000 and \$439,000, respectively, in time charges relating to project management for the three and six months ended June 30, 2014, year ended December 31, 2013 and from March 8, 2011 (Inception) to June 30, 2014, respectively. These charges have been credited to additional paid-in capital.

NOTE 6 - CONCENTRATIONS:

Cash

The Company maintains cash balances in a financial institution. At various times during the period, balances may have exceeded insured limits.

Vendor

The Company sub-contracts its research and development to a vendor which accounted for 58%, 45%, 59% and 77% of total expenses incurred for the for three and six months ended June 30, 2014, year ended December 31, 2013, and from March 8, 2011 (Inception) to June 30, 2014, respectively.

NOTE 7 - OTHER COMMITMENTS:

In February 2014, the Company issued a purchase order for the manufacture of the Epidural and Intra-Articular instruments for the production of a total of five hundred (500) instruments. The total commitment under this purchase order is \$913,750. A total of \$350,000 was previously advanced in 2013 for the long lead time parts. The instruments are expected to be delivered through December 2014.

The Company has a commitment with a third party consulting group to conduct human factor studies of the Company's instruments. The cost of this study is estimated to be approximately \$98,000. This study will take place in 2014.

In July 2013, Milestone Scientific Inc, (as an agent for Milestone Medical Inc), entered a strategic partnership with the largest provider of specialty sales and distribution solutions for healthcare in the United States. During the three year strategic partnership, the distributor will hold the exclusive rights to market, resell, label and distribute Milestone's *CompuFlo* injection technology for use in epidural applications for childbirth and other pain management needs in hospitals in the U.S.

3. Information on the rules applied to the preparation of the report, including information on the changes in applied account rules (policies).

2Q 2014 report was prepared in accordance with the rules indicated in Exhibit 3 to the Alternative Trading System Rules “Current and Periodical Information in the Alternative Trading System on the NewConnect market”. Information on applied accounting rules (policies) was presented in Note 2 to the Financial Statement.

4. Brief description of the most important achievements or failures of the issuer during the period of the report as well as a description of the most important factors and events, in particular atypical ones, which impact the achieved results.

During the second quarter ending June 30, 2014, the Issuer continued the process of obtaining regulatory approval for the two medical instruments (Epidural and Intra-Articular Injections Systems). The regulatory approval process is both for the USA (FDA) and the European Community (CE) and both are progressing at different rates of completion. The Company hired two full time employees; a Director of Sales and Business Development and an instrument trainer. Additionally, the Company is continuing its efforts to identify and meet with potential distributors for both instruments throughout the world. The Issuer’s two employees are actively traveling throughout Europe and the USA presenting new instruments to prospective medical distributors. This is an ongoing process, but it is important to have the respective distributors identified and ready to begin the sales process once regulatory approval is received. Additionally, beginning July 1, 2014, the Company has retained the services of a marketing expert to assist on the launch and growth of these two instruments. As announced last year, the Issuer already has a distribution channel in place with one of the largest specialty distributors of healthcare products in the United States to market and sell the Company epidural instrument. The Issuer looks forward to creating similar agreements in other markets this year. There were no failures noted during the quarter.

5. A description of the status of implementation of activities and investments of the issuer and the timetable of their implementation

The Issuer expects to commence marketing and sale of its epidural instruments, following obtaining U.S. FDA or CE (European Markets) marketing clearance, which approval is expected before the end of for the CE (European Market). The FDA regulatory market clearance will not be achieved until second or third of 2015. The process is continuing to move forward at a slower rate than previously anticipated but the direction is still optimistic. Since the Issuer's intra-articular instrument is at an earlier stage of development and further development of that instrument and its disposable to reflect the needs and preferences of potential users is expected marketing and sales will occur at a later date, even if the U.S. FDA marketing clearance is obtained on the recently filed application. Marketing and sale of the intra-articular instrument is expected to begin approximately one year following FDA marketing approval.

As announced earlier this year, the Company Board of Directors has approved plans for the Issuer to uplist from NewConnect Market to the Main Market of the Warsaw Stock Exchange, which we expect to occur in the second half of this year, subject to approval of the Company's Prospectus. Transitioning to the Main Market of the Warsaw Stock Exchange will be an important development for the Issuer as the Issuer believes this will help increase awareness and expand the number of potential investors in the company. In tandem with the uplisting, we expect to complete a public offering of the Company shares, which we expect will occur at a substantial premium to the Company prior offering.

6. If the issuer took initiatives to develop its activities aimed to implement innovative solutions at the enterprise during the period of the report – information on such activities

The Issuer continues to consider and where appropriate include innovative initiatives for its two medical instruments. In fact, the Company is in the process of preparing an application to the National Centre for Research and Development 2014 initiative under the Demonstrator Program for a grant to expand the utilization and future development of the instruments.

The purpose of the program is for strengthening the transfer of research funding to the economy supporting scientifically – development undertaking in developing new technology or product including testing the developed solution in the demonstrative scale. During the quarter, there were no other new initiatives, other than those described in Item #4, above.

7. Description of the organization of the group indicating consolidated entities

Up to the date of this report completion, the Issuer does not have any subsidiary, so it does not contribute a capital group. For this reason, the Issuer does not purpose consolidated financial statements.

Leonard A. Osser
Chief Executive Officer